1,721,884 research outputs found
EXPRESSION OF P73 IN MYELOMA CELL LINES AND PLASMA CELLS OF MULTIPLE MYELOMA PATIENTS
Get PDFBackground: Multiple myeloma (MM) Is a B-cell malignancy characterised by the accumulation of clonal plasma cells in the bone marrow. Myeloma biology is heterogeneous and this lead to a different clinical behavior. As for other type of cancers, hypermethylation could be a mechanism of resistance in myeloma. Hence, DNA methylation of p73 tumor-suppressor gene can potentially be biomarker for diagnosis or relapse in MM.
Aim: The goal of this study was to identify the expression of p73 in myeloma evaluating it in 24 different myeloma cell lines and in multiple myeloma patients. Methods: we evaluated the expression of p73 by q-PCR in 24 HMCL and 6 patients, 2 with MGUS, 2 with MM at diagnosis and 2 with relapsed/refractory MM. We tested the expression of p73 in some HMCL, one per category, by western blot. Moreover, we analyzed the expression of p73 before and after treatment with 5- aza-2-deoxycytidine.
Results: 14/21 HMCL (66.7%) did not express p73 to a significant level, 4/21 (19%) have been shown to express the gene and its encoded protein to low levels and only 3/21 (14.3%) expressed p73 to an intermediate level. By western blot, we observed that the protein has a very low concentration in all three categories, considered unexpressed. We have observed that 6/12 (50%) cell lines treated increased the expression of the gene p73 after treatment with 5-aza-2- deoxycytidine, but is not reflected in increasing production of the protein detected by western blot. Finally, we observed that 2/6 (33%) patients expressed the gene at low level and 4/6 (67%) patients did not express p73.
Conclusions: Our data do not provide evidence that the expression of p73 may be useful as prognostic indicators at MM diagnosis, because our study is limited to few patients tested. To better define and assess the clinical impact of the p73 expression in MM, it is therefore necessary to test the expression of p73 also in a larger number of patient samples with multiple myeloma.
This knowledge may help to develop new markers for detection of minimal residual disease and determine candidate patients for epigenetically targeted salvage therapy regimens
CIRCSE/LucaniPharsalia: Lucani Pharsalia
No full textRDF version of the Lucani Pharsalia. The Pharsalia is an epic poem in 10 books written by Lucan in 1st century AD. It portrays the civil war between Caesar and the Senate's forces, led by Pompey
Catalogo dei vasi. Vasi lucani
No full textselezione e schedatura analitica dei vasi lucani a figure rosse ritenuti ispirati a performance tragiche nella bibliografia precedent
Prefazione
No full textSi tratta della prefazione al testo di A. Restaino, Mode & modi dei Lucani, Venosa (Pz), Appia 2 Editric
Lucani Opera Romae:typis Officinae Polygraphicae ,1992
No full textItem does not contain fulltextRenato Badalì Lucani Opera Romae:typis Officinae Polygraphicae ,199
M. Annei Lucani Bellum Civile liber X
Get PDFContains fulltext :
61088.pdf (Publisher’s version ) (Open Access)E. Berti M. Annei Lucani Bellum Civile liber X Firenze:Felice le Monnier ,2000 880081295
Vincenzo Marinelli e gli artisti lucani dell'Ottocento
No full textVolume dedicato al pittore Vincenzo Marinelli e agli artisti lucani dell'Ottocento e del primo Novecento, protagonisti nelle arti figurative italiane ed europe
Periodici lucani digitalizzati: fonti per la storia della Basilicata
No full text"La Biblioteca nazionale di Potenza, attraverso la realizzazione del Progetto Digitalizzazione di periodici lucani microfilmati, si è prefissa l’obiettivo di creare un archivio digitale che documenti la storia lucana e che sia un valido punto di riferimento per lo studio e per la valorizzazione della Basilicata. Le testate digitalizzate si riferiscono a periodici lucani pubblicati tra il 1854 ed il 1954, i cui originali sono posseduti, per la maggior parte, dalla Biblioteca nazionale centrale..
Enotri e Lucani: continuità e discontinuità
No full textSi affronta, alla luce delle fonti e delle discussioni più recenti, il problema della continuità o discontinuità tra l'orizzonte degli Enotri e dei Lucani, valorizzando, in questa prospettiva le indicazioni ricavabili dai dati toponomastici
Effect of L-carnitine on plasma lipoprotein fatty acids pattern in patients with primary hyperlipoproteinemia
No full textPURPOSE: To investigate the effect of L-carnitine (L-C) administration on plasma lipoprotein fatty acids pattern in patients with primary hyperlipoprotinemia. PATIENTS AND METHODS: The effect of L-C on plasma lipoprotein fatty acids pattern was investigated in 24 male and female hyperlipoproteinemic patients, aged 51.3 +/- 7.8 years (lipoprotein phenotypes: IIb and IV, WHO, 1970). After hypolipidemic diet (P, 22%; C, 48%; L, 30%; S, 10%; M, 10%; PV, 10%, cholesterol < 300 mg/d) lasting 30 days, L-C was given at a daily dosage of 1 g t.i.d. for 90 days. RESULTS: Plasma total polyunsaturated to saturated fatty acids ratio (8/5) showed a statistically significant increase after L-C (baseline: 0.74 +/- 0.2, vs 120 days: 0.84 +/- 0.2; p < or = 0.03). A statistically significant decrease of HDLs 16:0 (baseline: 28.1 +/- 4.2 vs 120 days: 26.4 +/- 3.7; p < or = 0.002), HDL3s 16:0 (baseline: 28.6 +/- 4.5 vs 120 days: 26.9 +/- 3.6; p < or = 0.001) and VLDLs 14:0 (baseline: 2.0 +/- 0.8 vs 120 days: 1.6 +/- 0.6; p < or = 0.02), specular to a statistically significant increase of VLDL's 18:2 (baseline: 21.9 +/- 5.1 vs 120 days: 24.3 +/- 4.9; p < or = 0.01), was also observed. Plasma levels of total cholesterol and LDL-cholesterol were reduced after one month. Plasma apolipoprotein AI and B levels were significantly increased after 30 and 60 days of treatment with L-C. CONCLUSIONS: A less atherogenic plasma lipoprotein fatty acids profile was observed after 120 days of combined treatment with diet and L-C
- …
